Trial Profile

A Phase 1b Study Evaluating the Safety and Tolerability of CLB-4000 with or without Peg-IFNa-2a in Subjects with Chronic Hepatitis B: Randomised cohort

Status: Not yet recruiting

Phase of Trial: Phase I

Latest Information Update: 24 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

24 Nov 2025 New trial record
15 Oct 2025 According to ClearB Therapeutics media release, review of the safety data from the sentinel subject supported enrollment for the remainder of the cohort in their Phase 1b clinical study evaluating the therapeutic vaccine CLB-4000 (ACTRN12625000250437 and ACTRN12625000204448). Results are expected on a rolling basis starting 2H 2026.
07 Apr 2025 Last patient enrollment date is anticipated on 15/05/2026 and Last data collection date anticipated on 29/02/2028

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com